Why are trametinib and dabrafenib used together?

The combination of trametinib and dabrafenib is used to treat specific types of cancer, mainly based on their respective mechanisms of action and their synergistic effects when used together.

Dabrafenib is a BRAF inhibitor, mainly used to treat cancers with BRAF V600E or V600K mutations. It inhibits the proliferation and survival of tumor cells by directly inhibiting the activity of BRAF protein and blocking the upstream conduction of MAPK signaling pathway.

Trametinib is a MEK inhibitor that acts downstream of the MAPK signaling pathway. It further blocks the conduction of this signaling pathway by inhibiting the activity of MEK protein, forming a dual upstream and downstream blocking effect with dabrafenib.

Since dabrafenib and trametinib act on different nodes of the MAPK signaling pathway, their combined use can block the growth signals of tumor cells more comprehensively and effectively. This dual upstream and downstream blocking effect can significantly enhance the therapeutic effect, increase the apoptosis rate of tumor cells, and inhibit the growth and spread of tumors.

Multiple clinical trials have shown that dabrafenib combined with trametinib can significantly extend the progression-free survival (PFS) and overall survival (OS) of patients with BRAF mutated melanoma and non-small cell lung cancer. This extension of survival is of great significance to improving patients' quality of life and reducing the burden of disease.

When targeted drugs are used alone, tumor cells are prone to develop drug resistance. The combined use of dabrafenib and trametinib can reduce the occurrence of drug resistance, because even if tumor cells become resistant to one of the drugs, the other drug can still exert a therapeutic effect. This dual inhibitory effect helps maintain long-term therapeutic effects.

The combination of dabrafenib and trametinib has demonstrated a good safety profile in multiple clinical trials. Although there may be some side effects, most patients are able to tolerate it and continue treatment.